

„Give Life a Chance through Cancer Immunotherapy”

Új Rák Immunoterápiás Rendezvény - Szakmai Program

National Institute of Oncology, Budapest, 9th and 10th September 2016

9th September Morning session: 10. 00 am – 13. 30. (Eckhardt Lecture Hall/ National Institute of Oncology), General Opening: 10.00am – 11.00

1/ *Welcome: Prof Dr Miklós Kásler, MD, PhD, DSc, General Director of National Institute of Oncology*

2/ *Greetings from Hungarian American Fulbright Commission / CIES / US Embassy representative: “Building the (“Scientific”) Bridges between Nations” / following the Fulbright Mission (A Fulbright eszme nyomában)*

3/ *Opening remarks of Prof Dr Lisa H. Butterfield, Ph.D. Vice President of SITC, Director, UPCI Immunologic Monitoring and Cellular Products Laboratory, University of Pittsburgh, Upcoming President of Society for Immunotherapy of Cancer (SITC) and World Immuno Council (WIC) leadership representative. “The 2015-2016 SITC Immunotherapy Biomarkers Task Force”*

4/ *Welcome of Fulbright Alumni at the National Institute of Oncology, Prof Dr Mária Gódey, MD, PhD, Fulbrighter, Head of Department of Radiodiagnostics, Dr Beatrix Kotlan, PhD Conference Chair, Fulbrighter: “The impact of Fulbright Grant for Clinical and Research work for cancer care”*

5/ *Opening remarks with lecture of Prof Dr Gabriella Liszkay, MD, PhD, Conference Chair and Head of Oncoteam at National Institute of Oncology: New immunotherapeutic strategies in melanomas – in the National Institute of Oncology (Úttörő immunoterápiás lehetőségek melanómákban)*

11.30 – 11.55. COFFEE break

12.00: **Immunotherapy ROUND TABLE discussion:** Discussion topics: a/ Novel immunotherapeutic drug usage for cancer cure. b/ Immune related response. (Új immunoterápiás stratégiák lehetőségei és korlátai)

13.00: *“Guided educational visit “ to the Department of Radiodiagnostics at the National Institute of Oncology Prof Dr Mária Gódey, MD, PhD, Head of the Department: The great step forward in image analysis to reveal cancer metastases (Az Országos Onkológiai Intézet Radiodiagnosztikai Osztályának bemutatása)*

13.30 – 14.15. LUNCH break

9th September - Afternoon session: 2.15 – 18.00. (Eckhardt Lecture Hall/ National Institute of Oncology): The mosaic of cancer immunotherapy

1/ 14.15: *Prof Dr Lisa H. Butterfield, Ph.D. Vice President, Upcoming President of Society for Immunotherapy of Cancer (SITC) and World Immuno Council (WIC) leadership. Professor of Medicine, Surgery and Immunology, Director, UPCI Immunologic Monitoring and Cellular Products Laboratory, University of Pittsburgh, “Immune Modulation by Alpha Fetoprotein”*

2/ 14.40: *Prof Dr Yehuda Shoenfeld, MD, FCS, FACS Head of Zabludowicz Center for Autoimmune Diseases of Sheba Medical Center, Tel-Hashomer, Israel, Fulbrighter, “Adjuvant, autoimmunity and lymphoma –a continuum of a process”*

3/ 15.05: *Prof Dr Jean Luc Teillaud, PhD, DSc, Director at Centre de Recherche des Cordeliers/ INSERM,, Paris, France, "The vaccinal effect of anti-tumor antibodies: the CD20 case".*

4/ 15.30: *Prof Dr Mepur H Ravindranath, M.Sc., Ph.D., Former Fulbright Fellow, Research Scientist and Director at Terasaki Foundation Laboratory Los Angeles, CA, USA: HLA-E mediated Cancer Progression and development of HLA-E monospecific monoclonal antibodies with diagnostic and anti-tumor therapeutic potential.*

15.55 – 16.20. COFFEE break

5/ 16.20: *Prof Dr Zoltan Ivics, PhD, DSc*, Head of Division of Medical Biotechnology

Paul Ehrlich Institute, Langen, Germany. "Challenges with genetically modified cells, great possibilities and hardships of it"

6/ 16.40: *Prof Dr Zavodszky Peter, PhD, FCS, FACS*, Head of Innovation Foundation, Hungary, MTA, TTK, Budapest, Immunotherapy and the immunology beyond. Facts and challenges of lectins in the Host

7/ 17.05: *Prof Dr Andrzej Mackiewicz MD, PhD, DSc*, Chair of Medical Biotechnology, Poznan University of Medical Sciences, Greater Poland Cancer Centre, BioContract Sp. z o.o. Poznan, Poland, Past President of Polish Immunological Society, Potential and experience with novel melanoma therapeutic vaccines

8/ 17.30: *Prof Dr Janos Hunyady, MD, DSc*, National Institute of Oncology, and University of Debrecen, Hungary, A dendritikus sejtek, mint új immunterápiás lehetőségek előőrsei (Dendritic cells in the forefront for new immunotherapeutics).

9/ 17.50: *Prof Dr András Székács, PhD, DSc, Fulbrighter*, Director of the Agro-Environmental Research Institute. National Agricultural Research and Innovation Center, Budapest. Allowed genotoxicity of the chemicals we are exposed to.

10th September 2016, Morning session: 10.00. am – 13. 00 (Eckhardt Lecture Hall/ National Institute of Oncology): Immune system`s involvement for cancer therapy

1/ 10.00: *Prof Dr Herve W Fridman, MD, DSc*, Professor of Immunology and Vice-Dean at the Medical School Paris Descartes, Director at Centre de Recherche des Cordeliers/ INSERM, Paris France : "Integrating tumor microenvironment with cancer molecular classifications. Experiences in Colorectal carcinomas and renal cell carcinomas."

2/ 10.25: *Prof Dr József Timar, MD, PhD, DSc*, Director of Pathology Institute II, Semmelweis University, Budapest, Hungary. *Fulbrighter*, Immunotherapy in Head and Neck Cancers. Experiences and further possibilities.

3/ 10.50: *Prof Dr Catherine Santes-Fridman, PhD, DSc*, Professor of Immunology at University Paris-Descartes, Head of Cancer, Immunology and Immunopathology department Cordeliers Research Center, UMR, Pierre and Marie Curie University, Paris, Innovative therapies based on immunology. (The immune response in cancer: immunology, pathology, immunotherapy)

4/ 11.15: *Prof Dr Eytan Barnea, MD, FACOG*, Chief Scientist BioIncept, LLC, Chairman and Founder of the Society for the Investigation of early Pregnancy, Cherry Hill, NJ, USA, Potential therapy for immune-based cancers.

5/ 11.40: *Dr Andrea Ladanyi, PhD*, Tumorimmunology, Surgical and Molecular Tumorpathology, National Institute of Oncology. A tumorimmunológia új áttörései a rák kezelésében. (New breakthroughs in tumorimmunology. Educational message)

12.00 – 12.20: COFFEE break

12.20: *Prof Dr Nicola Mozzillo, MD, PhD* : Director Melanoma Surgery, National Cancer Institute of Naples, Naples, Italy. Immunotherapy meets electrotherapy. New achievements in it.

12.45: *Dr Peter Kemeny, MD, PhD*, Centre of Surgical Oncology, National Institute of Oncology, Budapest. Oncoplastic breast conserving surgery versus conventional breast conserving surgery. Long term retrospective analysis of 350 cases. (?)

13.05. – 13.35. **Újabb lehetőségek az immunonkológia területén**

(Further advances in Immuno-Oncology) (Symposium sponsored by Bristol-Myers Squibb Kft.)

- 13:05-13:20 A kombinált immunellenőrzőpont gátló terápia szerepe melanomában
(The role of the combined immune checkpoint inhibitor therapy in melanoma)
Professor Dr Gabriella Liskay, MD, PhD
- 13:20-13:35 Új perspektívák a veserák kezelésében az immunterápia segítségével
(New perspectives with immunotherapy in renal cell carcinoma)
Dr. Fruzsina Gyergyay, MD, PhD

13.35 – 13.55. *Introducing the Oncodermatology Department of National Institute of Oncology with Professor Dr Gabriella Liskay, MD, PhD, Conference Chair*

13.30. – 14.15. LUNCH break

10th September 2016, Afternoon session: 10.00. am – 13. 00 (Eckhardt Lecture Hall/ National Institute of Oncology): Harnessing the potentials of tumorimmunology for cancer cure

1/ 14.15: *Prof Dr Soldano Ferrone. MD, PhD-DF/HCC*, Professor in Residence of surgery, Harvard Medical School, The Harvard Clinical and Translational Science Center, Boston, USA, Immunology and Cancer. Friends or Foes? Or: The molecular basis and the clinical significance of HLA antigen defects in malignant cells.

2/ 14.40: *Prof Dr Gabriella Sarmay, PhD, DSc* Research Centre for Natural Sciences of the Hungarian Academy of Sciences, Budapest. Az immunrendszer kétélű kard – az érem másik oldala (Immune system: the double-edged sword – The other side of the picture)

3/ 15.05: *Prof Dr Miri Blank, PhD, DSc*, Head of Immunology Department at the Zabudowicz Center for Autoimmune Diseases of Sheba Medical Center, Tel-Hashomer, Israel: Natural human antibodies, IVIG and their potentials for cancer cure

4/ 15.30: *Dr Beatrix Kotlan, PhD, Fulbrighter*, National Institute of Oncology, Novel immunotherapeutic approaches – exceeding our imagination! (Új immunterápiás és génmanipulációs lehetőségek egy karnyújtásnyira tőlünk.)

15.50 – 16.10. COFFEE break

5/16.10: *Dr Bittner Nora, MD, PhD*, National Institute of Oncology, President of Hungarian League Against Cancer”, Conference Chair: A tüdőrák immunterápiája és mellékhatásai- eredmények és nehézségek (Immunotherapeutics for pulmonal cancers – achievements and hardships).

6/16.35: *Dr Marie-Caroline Dieu-Nosjean, PhD*, Laboratory "Cancer, Immune control and Escape" UMRS 1138 INSERM, Cordeliers Research Centre, Paris, France, “Emergence of Tertiary Lymphoid Structures as a first line of defense against tumors”

7/ 17.00: *Dr Ákos Sávolt MD, PhD*, Centre of Surgical Oncology, National Institute of Oncology Optimal Treatment of the Axilla, Surgery or Radiotherapy. Long term results of a prospectiv randomized study

8/ 17.25: **Team science discussion: Pioneering the trail of cancer Immunotherapy in Hungary**

9/ 17.50: *Closing Remarks*, Challenges and Controversies for choosing the acceptable therapy, Combination Therapies, Cancer Prevention Awareness
There might be some changes in the program schedule.

Dr Beatrix Kotlan, PhD
National Institute of Oncology
kotlanb@netscape.net,
224 8600/ 3294

Prof Dr Gabriella Liskay, MD, PhD,
Head of Oncoteam, Department Head of Oncodermatology,
National Institute of Oncology, Budapest
liskay@oncol.hu